Outcome Measures
bleeding, neutropenia, toxicity, anemia, neuropathic, transaminitis, gastrointestinal and intracerebral hemorrhage, peripheral and optic neuropathy
BLEEDING, NEUTROPENIA, ADVERSE EVENTS, THROMBOCYTOPENIA, ANEMIA
The primary end point of the study was the cumulative proportion of participants experiencing adverse events of special interest (AESI) or dying by 56 days. AESI were selected based on anticipated toxicity related to the 2 interventional arms: bleeding (gastrointestinal and intracerebral hemorrhage), hematological (anemia, neutropenia, thrombocytopenia), transaminitis, and neuropathic (peripheral and optic neuropathy; 